GO:0046850 regulation of bone remodeling: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046850 regulation of bone remodeling describes any process that modulates the frequency, rate, or extent of bone remodeling, the coupled formation and resorption that maintains skeletal integrity.
• The RANKL/RANK/OPG axis is the central cytokine system controlling osteoclast differentiation and bone resorption, and its balance determines net bone mass.
• Systemic hormones, growth factors, circadian clocks, epigenetic modifiers, and immune signals all converge to regulate bone remodeling.
• Dysregulation of bone remodeling underlies osteoporosis, periodontitis-related bone loss, bone metastasis, and inflammatory bone diseases.
• Key research models include RANKL, RANK, OPG, RUNX2, SP7, SOST, and vitamin K-dependent proteins, studied with knockout, knock-in, and overexpression approaches.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of regulatory nodes in bone remodeling.
Description
Bone is a dynamic tissue that is continuously renewed through bone remodeling, a coupled process of osteoclastic bone resorption and osteoblastic bone formation. The Gene Ontology term GO:0046850, regulation of bone remodeling, captures any process that modulates the frequency, rate, or extent of these remodeling events, thereby maintaining skeletal integrity. This term is essential for researchers because disruptions in remodeling regulation are directly linked to common skeletal diseases such as osteoporosis, inflammatory bone loss, and bone metastasis. Understanding the regulatory layers of bone remodeling requires integrating cytokine signaling, systemic hormones, growth factors, epigenetic control, and circadian rhythms. The RANKL/RANK/OPG system remains the best-characterized molecular axis, but many additional regulators have been identified through genetic and pharmacological studies. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0046850, its mechanisms, key genes, disease relevance, and experimental methods for functional genomics.
regulation of bone remodeling At A Glance
| GO ID | GO:0046850 |
|---|---|
| GO term | regulation of bone remodeling |
| Ontology | biological_process |
| Synonym | regulation of bone remodelling |
| Major function | Modulates the frequency, rate, or extent of bone formation and resorption to maintain skeletal integrity |
| Key regulators | RANKL/RANK/OPG axis, systemic hormones, growth factors, circadian clock, epigenetic modifiers |
| Associated diseases | Osteoporosis, periodontitis, bone metastasis, inflammatory bone loss |
| Research models | Knockout, knock-in, point-mutation, overexpression cell and animal models |
What Is GO:0046850?
GO:0046850 regulation of bone remodeling is defined as any process that modulates the frequency, rate, or extent of bone remodeling, the processes of bone formation and resorption that combine to maintain skeletal integrity. In other words, it encompasses all molecular and cellular events that adjust the balance between osteoclast-mediated resorption and osteoblast-mediated formation, including cytokine signaling, hormonal control, transcriptional regulation, and epigenetic modifications.
Why Is regulation of bone remodeling Important in Cell Biology?
Regulation of bone remodeling is critically important because an imbalance in this process leads to skeletal fragility, inflammatory bone destruction, and metastatic bone disease. The RANKL/RANK/OPG system serves as the principal regulatory axis, and its dysregulation is directly implicated in postmenopausal osteoporosis and cancer-induced bone loss. Moreover, systemic factors such as vitamin K2, growth factors, and circadian rhythms further modulate remodeling, offering multiple entry points for therapeutic intervention. Understanding GO:0046850 is therefore fundamental for developing targeted treatments for bone disorders and for interpreting genetic variants that affect skeletal homeostasis.
• Maintains skeletal integrity by balancing bone resorption and formation.
• Dysregulation causes osteoporosis and increased fracture risk.
• RANKL/RANK/OPG axis is a validated drug target for bone loss.
• Periodontitis involves immune-mediated regulation of periodontal bone remodeling.
• Bone metastasis hijacks remodeling regulation to support tumor growth.
• Circadian regulation of bone remodeling influences diurnal bone turnover.
• Vitamin K2 modulates bone remodeling and may benefit bone health.
• Epigenetic mechanisms regulate bone remodeling and bone metastasis.
• Growth factors and systemic hormones fine-tune remodeling activity.
• CRISPR models enable causal testing of regulatory genes in bone cells.
What Happens During regulation of bone remodeling?
Initiation of Bone Remodeling
In simple terms: Bone remodeling starts when old or damaged bone is targeted for removal.
Bone remodeling is initiated by signals that recruit osteoclast precursors to specific sites on the bone surface. The RANKL/RANK/OPG axis is the key cytokine system that controls osteoclast differentiation and activation, with RANKL binding to RANK on osteoclast precursors and OPG acting as a decoy receptor. This initiation phase is regulated by systemic hormones, mechanical loading, and local factors that determine where and when remodeling occurs.
Osteoclast Differentiation and Resorption
In simple terms: Specialized cells called osteoclasts dissolve old bone.
Upon RANKL stimulation, osteoclast precursors differentiate into mature osteoclasts that resorb bone by secreting acid and proteases. This resorption phase is tightly regulated by OPG, which limits RANKL availability, and by immune signals in inflammatory conditions such as periodontitis. The extent of resorption determines the amount of bone that must be subsequently formed.
Coupling to Bone Formation
In simple terms: After old bone is removed, new bone is built to replace it.
Bone resorption is coupled to bone formation through factors released from the bone matrix and from osteoclasts themselves, which stimulate osteoblast differentiation. Osteoblasts then synthesize new bone matrix and regulate its mineralization. This coupling ensures that resorbed bone is replaced, maintaining skeletal integrity.
Systemic and Local Regulation
In simple terms: Hormones, vitamins, and local signals adjust the speed of bone remodeling.
Systemic regulators such as parathyroid hormone, vitamin D, and vitamin K2 modulate bone remodeling by affecting osteoblast and osteoclast activity. Growth factors including IGF-1 and TGF-beta are released during resorption and influence subsequent formation. Circadian rhythms also regulate bone remodeling, with diurnal variation in bone turnover markers.
Epigenetic and Immune Modulation
In simple terms: Chemical tags on DNA and immune signals can dial bone remodeling up or down.
Epigenetic mechanisms, including DNA methylation and histone modifications, regulate the expression of genes involved in bone remodeling and bone metastasis. In periodontitis, host immune microenvironment factors modulate periodontal bone remodeling through cytokines and immune cell interactions. These layers add complexity and provide additional targets for therapeutic intervention.
Key Genes Involved in GO:0046850 regulation of bone remodeling
The following genes and proteins are central to the regulation of bone remodeling, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFSF11 (RANKL) | Key cytokine that binds RANK to induce osteoclast differentiation | Central regulator of bone resorption; target for osteoporosis therapy |
| TNFRSF11A (RANK) | Receptor for RANKL on osteoclast precursors | Mediates osteoclastogenesis; mutations cause bone disorders |
| TNFRSF11B (OPG) | Decoy receptor for RANKL, inhibits osteoclastogenesis | Regulates bone mass; therapeutic potential |
| RUNX2 | Master transcription factor for osteoblast differentiation | Essential for bone formation; studied in knockout models |
| SP7 (Osterix) | Transcription factor required for osteoblast differentiation | Key regulator of bone formation |
| SOST (Sclerostin) | Inhibits Wnt signaling and bone formation | Target for osteoporosis therapy; knockout increases bone mass |
| CTNNB1 (Beta-catenin) | Wnt signaling effector in osteoblasts | Regulates bone mass; mutations affect skeletal development |
| VDR | Vitamin D receptor mediating hormonal control | Regulates calcium and bone remodeling |
| PTH | Parathyroid hormone regulates calcium and bone turnover | Anabolic and catabolic effects on bone; therapeutic use |
| IGF1 | Growth factor promoting osteoblast function | Systemic regulator of bone remodeling |
| TGFB1 | Growth factor released during resorption, couples formation | Regulates osteoblast recruitment |
| MGP | Vitamin K-dependent protein inhibiting vascular calcification | Linked to bone remodeling and vitamin K2 effects |
| BGLAP (Osteocalcin) | Vitamin K-dependent bone protein | Marker of bone formation; regulated by vitamin K2 |
| NFATC1 | Transcription factor essential for osteoclast differentiation | Downstream of RANK; knockout causes osteopetrosis |
| CTSK (Cathepsin K) | Protease secreted by osteoclasts for bone resorption | Target for osteoporosis drugs; knockout causes osteopetrosis |
| MMP9 | Matrix metalloproteinase involved in bone resorption | Regulates osteoclast migration and resorption |
| IL6 | Cytokine that promotes osteoclastogenesis | Immune regulation of bone remodeling in inflammation |
| TNF | Pro-inflammatory cytokine stimulating bone resorption | Mediates inflammatory bone loss |
How Is regulation of bone remodeling Regulated?
Regulation of bone remodeling is controlled at multiple levels. The RANKL/RANK/OPG axis is the central cytokine system, where the ratio of RANKL to OPG determines osteoclast activity. Systemic hormones such as parathyroid hormone and vitamin D modulate this axis, while growth factors like IGF-1 and TGF-beta influence osteoblast function. Vitamin K2 has been shown to regulate bone remodeling by supporting osteoblast activity and inhibiting osteoclastogenesis. Circadian clock genes regulate bone remodeling, with diurnal rhythms in bone turnover. Epigenetic modifiers, including DNA methyltransferases and histone deacetylases, control the expression of key remodeling genes. In inflammatory conditions, immune cells and cytokines such as IL-6 and TNF modulate periodontal bone remodeling.
regulation of bone remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFSF11 (RANKL) | Osteoporosis, inflammatory bone loss | Knockout and overexpression in osteoblast/osteoclast co-cultures |
| TNFRSF11B (OPG) | Osteoporosis, bone metastasis | Knock-in of point mutations to alter RANKL binding |
| RUNX2 | Cleidocranial dysplasia, bone formation defects | Knockout and point-mutation in osteoblast cell lines |
| SOST | Sclerosteosis, osteoporosis | Knockout and overexpression in osteocytes |
| MGP | Keutel syndrome, vascular calcification | Knockout and vitamin K2 treatment models |
Osteoporosis
Osteoporosis results from an imbalance in bone remodeling where resorption exceeds formation, leading to reduced bone mass and increased fracture risk. The RANKL/RANK/OPG axis is a major therapeutic target, and vitamin K2 has been studied for its beneficial effects on bone health. Dysregulation of osteoblast and osteoclast activity is central to disease pathogenesis.
Periodontitis and Inflammatory Bone Loss
Periodontitis is characterized by immune-mediated destruction of periodontal bone, driven by host immune microenvironment factors that regulate bone remodeling. Pro-inflammatory cytokines such as IL-6 and TNF promote osteoclastogenesis, tipping the balance toward bone resorption. Understanding these immune interactions is critical for developing host-modulatory therapies.
Bone Metastasis
Bone metastasis involves cancer cells hijacking the bone remodeling process to create a favorable microenvironment for tumor growth. Epigenetic regulation of bone remodeling genes contributes to metastatic progression, and targeting these mechanisms may provide new therapeutic avenues. The RANKL/RANK/OPG system also plays a role in cancer-induced bone disease.
From regulation of bone remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate osteoclast differentiation? | Knockout of gene X in RAW264.7 cells followed by RANKL stimulation |
| Does a point mutation in gene Y affect bone formation? | Point-mutation knock-in in MC3T3-E1 osteoblast cells |
| Does overexpression of gene Z increase bone mass? | Overexpression in osteoblast precursor cells and in vivo models |
| Does gene W regulate circadian bone remodeling? | Knockout of clock genes in osteoblasts and circadian analysis |
| Does epigenetic modifier E control bone remodeling genes? | Knockout or knockdown of E in osteoblasts followed by RNA-seq |
| Does immune factor I modulate periodontal bone loss? | Knockout of I in mouse periodontitis models |
How to Study the regulation of bone remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on bone cell differentiation | Identify novel regulators of osteoclastogenesis |
| RNA-seq | Transcriptional changes during remodeling | Map gene expression networks in osteoblasts/osteoclasts |
| ATAC-seq | Chromatin accessibility | Identify regulatory elements controlling remodeling genes |
| Proteomics | Protein abundance and secretion | Discover coupling factors and biomarkers |
| Histomorphometry | Bone formation and resorption rates | Validate in vivo effects of genetic modifications |
| Micro-CT | Bone mass and microarchitecture | Assess bone phenotype in knockout/knock-in models |
| ELISA | RANKL, OPG, and cytokine levels | Quantify regulatory factors in serum or conditioned media |
| Circadian analysis | Diurnal variation in bone turnover | Study clock gene regulation of bone remodeling |
CRISPR-Cas9 Knockout Screening
CRISPR knockout screens enable systematic identification of genes that regulate bone remodeling. Libraries targeting epigenetic modifiers or signaling components can be introduced into osteoblast or osteoclast precursor cells, followed by selection under differentiation conditions. This approach has revealed novel regulators of osteoclastogenesis and osteoblast differentiation.
Transcriptomic and Epigenomic Profiling
RNA-seq and ATAC-seq can map gene expression and chromatin accessibility changes during bone remodeling. These methods identify transcriptional networks controlled by RUNX2, SP7, and NFATC1, and reveal epigenetic modifications that regulate remodeling genes.
Proteomic and Secretome Analysis
Proteomics of osteoblast and osteoclast cultures can identify secreted factors that mediate coupling between resorption and formation. Mass spectrometry-based approaches quantify RANKL, OPG, and matrix proteins, providing insights into regulatory mechanisms.
In Vivo Bone Histomorphometry
Histomorphometric analysis of bone sections from genetically modified mice quantifies osteoclast and osteoblast parameters, directly assessing the impact of regulatory genes on bone remodeling. This method is gold-standard for validating in vitro findings.
How CRISPR Can Be Used to Study GO:0046850 regulation of bone remodeling
Knockout
CRISPR knockout of genes such as TNFSF11, TNFRSF11A, or RUNX2 in osteoblast and osteoclast precursor cell lines provides definitive loss-of-function evidence for their role in bone remodeling. Knockout models are essential for validating candidate regulators identified in screens.
Point Mutation
Point mutations can be introduced to model human disease variants or to dissect specific domains of regulatory proteins. For example, point mutations in TNFRSF11B (OPG) that alter RANKL binding can reveal structural requirements for inhibition of osteoclastogenesis. This approach is valuable for understanding functional consequences of SNPs associated with bone density.
Knock-in
Knock-in of reporter genes or epitope tags into endogenous loci allows real-time monitoring of gene expression and protein localization during bone remodeling. Tagged knock-in of RUNX2 or SP7 enables chromatin immunoprecipitation to identify direct target genes.
Overexpression
Overexpression of regulatory genes such as SOST or MGP in osteoblastic cells can model gain-of-function states and test therapeutic hypotheses. Overexpression studies complement knockout approaches to establish causality in bone remodeling regulation.
How EDITGENE Supports regulation of bone remodeling Research
Researchers studying regulation of bone remodeling-related genes often need to determine whether a candidate gene is causally involved in osteoclast or osteoblast differentiation, and whether specific mutations alter its function. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for regulation of bone remodeling research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LEP Knockout HEK293 Cell Line | EDJ-KQ506 | Human | 3952 | Details Get a Quote |
| LEPR Knockout HEK293 Cell Line | EDJ-KQ507 | Human | 3953 | Details Get a Quote |
| DLK1 Knockout HEK293 Cell Line | EDJ-KQ1971 | Human | 8788 | Details Get a Quote |
| SYT7 Knockout HEK293 Cell Line | EDJ-KQ6449 | Human | 9066 | Details Get a Quote |
| SUCO Knockout HEK293 Cell Line | EDJ-KQ10389 | Human | 51430 | Details Get a Quote |
| SUCO Knockout A-549 Cell Line | EDJ-KQ39036 | Human | 51430 | Details Get a Quote |
| SUCO Knockout HCT 116 Cell Line | EDJ-KQ39038 | Human | 51430 | Details Get a Quote |
| SUCO Knockout HeLa Cell Line | EDJ-KQ39039 | Human | 51430 | Details Get a Quote |
| LEPR Knockout A-549 Cell Line | EDJ-KQ18828 | Human | 3953 | Details Get a Quote |
| LEPR Knockout HCT 116 Cell Line | EDJ-KQ18829 | Human | 3953 | Details Get a Quote |
| LEPR Knockout HeLa Cell Line | EDJ-KQ18830 | Human | 3953 | Details Get a Quote |
| SYT7 Knockout A-549 Cell Line | EDJ-KQ30516 | Human | 9066 | Details Get a Quote |
| SYT7 Knockout HCT 116 Cell Line | EDJ-KQ30517 | Human | 9066 | Details Get a Quote |
| MDK Knockout HEK293 Cell Line | EDJ-KQ50435 | Human | 4192 | Details Get a Quote |
| LEP Knockout HeLa Cell Line | EDJ-KQ53787 | Human | 3952 | Details Get a Quote |
Displaying Records 1 To 15 Of 25 Records
Frequently Asked Questions About regulation of bone remodeling
What is GO:0046850 regulation of bone remodeling?
GO:0046850 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate, or extent of bone remodeling, the coupled formation and resorption that maintains skeletal integrity.
What genes are involved in regulation of bone remodeling?
Key genes include TNFSF11 (RANKL), TNFRSF11A (RANK), TNFRSF11B (OPG), RUNX2, SP7, SOST, and CTNNB1, among others.
How does RANKL regulate bone remodeling?
RANKL binds to RANK on osteoclast precursors, inducing their differentiation and activation, while OPG acts as a decoy receptor to limit this process.
What diseases are associated with dysregulation of bone remodeling?
Osteoporosis, periodontitis, bone metastasis, and inflammatory bone loss are major diseases linked to dysregulated bone remodeling.
How is bone remodeling regulated by vitamin K2?
Vitamin K2 supports osteoblast activity and inhibits osteoclastogenesis, thereby modulating bone remodeling.
What is the role of circadian rhythms in bone remodeling?
Circadian clock genes regulate bone remodeling, leading to diurnal variation in bone turnover markers.
How do epigenetic mechanisms regulate bone remodeling?
Epigenetic modifications such as DNA methylation and histone acetylation control the expression of genes involved in bone remodeling and metastasis.
What experimental models are used to study regulation of bone remodeling?
Common models include knockout and transgenic mice, osteoblast and osteoclast cell lines, and CRISPR-engineered cells.
How can CRISPR be used to study bone remodeling genes?
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of candidate genes in bone cells.
What is the role of immune signals in periodontal bone remodeling?
In periodontitis, host immune microenvironment factors and cytokines such as IL-6 and TNF modulate periodontal bone remodeling, often promoting resorption.
Conclusion
GO:0046850 regulation of bone remodeling is a central biological process that integrates cytokine signaling, systemic hormones, growth factors, epigenetic control, and circadian rhythms to maintain skeletal integrity. Dysregulation of this process underlies prevalent skeletal diseases, making it a critical area for therapeutic development. Advances in CRISPR-based functional genomics now allow precise dissection of regulatory mechanisms, offering new opportunities for drug discovery and personalized medicine.
References
- 1. Kikyo N. 2024. Circadian Regulation of Bone Remodeling.. Int J Mol Sci 25(9) PMID: 38731934
- 2. Han N et al.. 2023. Regulation of the Host Immune Microenvironment in Periodontitis and Periodontal Bone Remodeling.. Int J Mol Sci 24(4) PMID: 36834569
- 3. Sharma G et al.. 2024. Epigenetic regulation of bone remodeling and bone metastasis.. Semin Cell Dev Biol 154(Pt C):275-285 PMID: 36379849
- 4. Boyce BF et al.. 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling.. Arch Biochem Biophys 473(2):139-46 PMID: 18395508
- 5. Siddiqui JA et al.. 2016. Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement.. Physiology (Bethesda) 31(3):233-45 PMID: 27053737
- 6. Hadjidakis DJ et al.. 2006. Bone remodeling.. Ann N Y Acad Sci 1092:385-96 PMID: 17308163
- 7. Myneni VD et al.. 2017. Regulation of bone remodeling by vitamin K2.. Oral Dis 23(8):1021-1028 PMID: 27976475
- 8. Kenkre JS et al.. 2018. The bone remodelling cycle.. Ann Clin Biochem 55(3):308-327 PMID: 29368538
